Related Experiment Video

Updated: Aug 17, 2026

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Treatment of children and adolescents with multiple sclerosis

Brenda Banwell1

  • 1University of Toronto, Pediatric Multiple Sclerosis Clinic, ON, Canada. brenda.banwell@sickkids.ca

Expert Review of Neurotherapeutics
|June 9, 2005
PubMed

Insights

Pediatric multiple sclerosis (MS) is increasingly diagnosed. Early treatment with immunomodulatory therapies, proven effective in adults, is crucial for children facing decades of MS to improve long-term outcomes.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Multiple sclerosis (MS) onset in children and adolescents is increasingly recognized.
  • Approved immunomodulatory therapies exist for adult MS, but their use in pediatrics is less established.
  • Early intervention in MS is critical for long-term outcomes, especially in pediatric patients facing decades of disease activity.

Purpose of the Study:

  • To review current multiple sclerosis therapies available for adults.
  • To summarize efficacy data of these therapies from adult studies.
  • To discuss the limited information on pediatric multiple sclerosis treatment and future therapeutic directions.

Main Methods:

  • Literature review of available immunomodulatory therapies for multiple sclerosis.
  • Analysis of efficacy data from adult clinical trials.
  • Examination of existing studies and case reports on pediatric multiple sclerosis treatment.

Main Results:

  • Several immunomodulatory therapies are approved and effective in adults with multiple sclerosis.
  • Efficacy data in pediatric populations are limited, with some evidence suggesting potential benefits.
  • The long-term impact of early treatment in pediatric MS requires further investigation.

Conclusions:

  • Early treatment of pediatric multiple sclerosis with available therapies may improve long-term outcomes.
  • Further research is needed to establish optimal treatment strategies and efficacy in children and adolescents.
  • Addressing specific challenges in pediatric MS management is crucial for improving patient prognosis.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...